How many 8-K filings has Cyclerion Therapeutics, Inc. filed?

Cyclerion Therapeutics, Inc. (CYCN) has 9 8-K (Current Event Report) filings on record, spanning Apr 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Cyclerion Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Cyclerion Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Cyclerion Therapeutics, Inc. (CYCN) — 8-K Filings

All 8-K filings from Cyclerion Therapeutics, Inc.. Browse 9 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (9)

Cyclerion Therapeutics Files 8-K — Dec 1, 2025 Risk: low
Cyclerion Therapeutics, Inc. filed an 8-K on December 1, 2025, reporting an event under 'Other Events'. The filing does not contain specific financial transacti
Cyclerion Therapeutics Files 8-K for Material Definitive Agreement — Sep 23, 2025 Risk: medium
On September 19, 2025, Cyclerion Therapeutics, Inc. entered into a material definitive agreement. The company, headquartered in Cambridge, MA, filed an 8-K repo
Cyclerion Therapeutics Files 8-K on Shareholder Votes & Financials — Jun 18, 2025 Risk: low
Cyclerion Therapeutics, Inc. filed an 8-K on June 18, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing da
Cyclerion Therapeutics Files 8-K Report — May 7, 2025 Risk: medium
On May 7, 2025, Cyclerion Therapeutics, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial stat
Cyclerion Therapeutics Files 8-K on Material Agreement — Mar 25, 2025 Risk: medium
On March 21, 2025, Cyclerion Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equi
Cyclerion Therapeutics Files 8-K: Material Agreement — Dec 17, 2024 Risk: medium
On December 13, 2024, Cyclerion Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes Regulation FD Disclosure and Financial
Cyclerion Therapeutics Files 8-K — Aug 7, 2024 Risk: low
Cyclerion Therapeutics, Inc. filed an 8-K on August 7, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not con
Cyclerion Therapeutics Files 8-K — Jun 14, 2024 Risk: low
Cyclerion Therapeutics, Inc. filed an 8-K on June 14, 2024, to report on matters submitted to a vote of security holders and to file financial statements and ex
Cyclerion Therapeutics Files 8-K — Apr 18, 2024 Risk: low
On April 18, 2024, Cyclerion Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no speci

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX